Gianluca Pandolfo

Prof. Gianluca Pandolfo

University of Messina, Messina, Italy
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2014 in The Scientific World Journal
Verified
Journal Article
Open access
PDF file
GSGiuseppe Scimeca
Giuseppe Scimeca
ABAntonio Bruno
Antonio Bruno
LCLucia Cava
Lucia Cava
GPGianluca Pandolfo
Gianluca Pandolfo
Maria Rosaria Anna MuscatelloMaria Rosaria Anna Muscatello
Maria Rosaria Anna Muscatello
RZRocco Zoccali
Rocco Zoccali
We aimed to assess whether Internet addiction (IA) severity was related to alexithymia scores among high school students, taking into account the role of gender differences and the possible effect of anxiety, depression, and age. Participants in the study were 600 students (ages ranging from 13 to 22; 48.16% girls) recruited from three high schools in two cities from Southern Italy. Participants completed a sociodemographic questionnaire, the Toronto Alexithymia Scale, the Internet Addiction Test, the Hamilton Anxiety Scale, and the Hamilton Depression Scale. The findings of the study showed that IA scores were associated with alexithymia scores, over and above the effect of negative emotions and age. Students with pathological levels of alexithymia reported higher scores on IA severity. In particular, results showed that difficulty in identifying feelings was significantly associated with higher scores on IA severity. No effect of gender was found. Implications for clinicians were discussed.

1 April 2011 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
Maria Rosaria Anna MuscatelloMaria Rosaria Anna Muscatello
Maria Rosaria Anna Muscatello
Antonio BrunoAntonio Bruno
Antonio Bruno
GPGianluca Pandolfo
Gianluca Pandolfo
UMUmberto Micò
Umberto Micò
GSGiuseppe Scimeca
Giuseppe Scimeca
RZRocco A. Zoccali
Rocco A. Zoccali
Based on the evidence that aripiprazole added to serotonin reuptake inhibitors (SRIs) or clomipramine in treatment-resistant obsessive-compulsive disorder (OCD) has reported promising results, the present 16-week, double-blind, randomized, placebo-controlled trial had the aim to explore the efficacy of aripiprazole add-on pharmacotherapy on clinical symptoms and cognitive functioning in a sample of treatment-resistant OCD patients receiving SRIs. After clinical and neurocognitive assessments, patients were randomly allocated to receive, in a double-blind design, 15 mg/d of aripiprazole or a placebo. A final sample of 30 patients completed the study. The results obtained indicate that aripiprazole added to stable SRI treatment substantially improved obsessive-compulsive symptoms as measured by changes on the Yale-Brown Obsessive Compulsive Scale total score and subscores (obsessions, P = 0.007; compulsions, P = 0.001; total score, P < 0.0001). Regarding cognitive functions, improvement was observed in some explored areas, such as attentional resistance to interference (Stroop score, P = 0.001) and executive functioning (perseverative errors, P = 0.015). The findings provide evidence that aripiprazole augmentation of SRIs/clomipramine treatment is well tolerated and may be proposed as an effective therapeutic strategy to improve outcome in treatment-resistant OCD.

20 February 2012 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
Antonio BrunoAntonio Bruno
Antonio Bruno
UMUmberto Micò
Umberto Micò
GPGianluca Pandolfo
Gianluca Pandolfo
DMDomenico Mallamace
Domenico Mallamace
EAElisabetta Abenavoli
Elisabetta Abenavoli
Maria Rosaria Anna MuscatelloMaria Rosaria Anna Muscatello
Maria Rosaria Anna Muscatello
The present 16-week double-blind, randomized, placebo-controlled trial had the aim to explore the efficacy of lamotrigine add-on pharmacotherapy on clinical symptomatology and cognitive functioning in a sample of patients with treatment-resistant obsessive–compulsive disorder (OCD) receiving serotonin reuptake inhibitors (SRIs). After clinical and neurocognitive assessments, patients were randomly allocated to receive, in a double-blind design, 100 mg/day of lamotrigine or a placebo. A final sample of 33 patients completed the study. The results obtained indicate that lamotrigine added to stable SRI treatment substantially improved obsessive–compulsive (Yale–Brown Obsessive Compulsive Scale: obsessions, p < 0.0001; compulsions, p < 0.0001; total score, p < 0.0001), and affective symptoms (Hamilton Rating Scale for Depression p < 0.0001). Regarding cognitive functions, improvement was observed only in Semantic Fluency ( p = 0.004). The findings provide evidence that lamotrigine augmentation of SRI treatment is well tolerated and may be proposed as an effective therapeutic strategy to improve outcome in treatment-resistant OCD.

1 April 2011 in Schizophrenia Research
Verified
Journal Article
Closed access
Maria Rosaria Anna MuscatelloMaria Rosaria Anna Muscatello
Maria Rosaria Anna Muscatello
Antonio BrunoAntonio Bruno
Antonio Bruno
GPGianluca Pandolfo
Gianluca Pandolfo
UMUmberto Micò
Umberto Micò
GSGiuseppe Scimeca
Giuseppe Scimeca
RZRocco A. Zoccali
Rocco A. Zoccali

1 January 2014 in World Journal of Gastroenterology
Verified
Journal Article
Open access
Maria Rosaria Anna MuscatelloMaria Rosaria Anna Muscatello
Maria Rosaria Anna Muscatello
Antonio BrunoAntonio Bruno
Antonio Bruno
GSGiuseppe Scimeca
Giuseppe Scimeca
GPGianluca Pandolfo
Gianluca Pandolfo
RZRocco A Zoccali
Rocco A Zoccali
Irritable bowel syndrome (IBS) is regarded as a multifactorial disease in which alterations in the brain-gut axis signaling play a major role. The biopsychosocial model applied to the understanding of IBS pathophysiology assumes that psychosocial factors, interacting with peripheral/central neuroendocrine and immune changes, may induce symptoms of IBS, modulate symptom severity, influence illness experience and quality of life, and affect outcome. The present review focuses on the role of negative affects, including depression, anxiety, and anger, on pathogenesis and clinical expression of IBS. The potential role of the autonomic nervous system, stress-hormone system, and immune system in the pathophysiology of both negative affects and IBS are taken into account. Psychiatric comorbidity and subclinical variations in levels of depression, anxiety, and anger are further discussed in relation to the main pathophysiological and symptomatic correlates of IBS, such as sensorimotor functions, gut microbiota, inflammation/immunity, and symptom reporting.

8 July 2010 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
PDF file
Maria Rosaria Anna MuscatelloMaria Rosaria Anna Muscatello
Maria Rosaria Anna Muscatello
Antonio BrunoAntonio Bruno
Antonio Bruno
GPGianluca Pandolfo
Gianluca Pandolfo
UMU Micò
U Micò
PBPm Bellinghieri
Pm Bellinghieri
RZR Zoccali
R Zoccali
The persistence of psychotic, affective, cognitive, and psychosocial symptoms despite medications is commonly observed in schizophrenic patients. The present study was a 24-week double-blind, randomized, placebo-controlled trial aimed to explore the efficacy of topiramate add-on pharmacotherapy on clinical symptomatology and cognitive functioning in a sample of treatment-resistant schizophrenic patients receiving clozapine. After clinical and cognitive assessments were randomly allocated to receive either up to 200 mg/day of topiramate or a placebo. A final sample of 43 patients completed the study. The results obtained indicate that topiramate appeared to be scarcely effective for reducing clinical symptomatology in schizophrenic patients who have had an incomplete clinical response to clozapine. Regarding cognitive functioning, in our sample a trend to experience cognitive impairment in the examined domains was observed, as the patients included in the topiramate groups expressed cognitive complaints partially confirmed by a mild worsening of performances on certain cognitive tasks. Schizophrenia is a heterogeneous disorder with regard to pathophysiology; therefore, data reflecting the mean response of a sample of patients may fail to reveal therapeutic effects. More research is needed to better identify subgroups of patients with peculiar features which may account for responsivity to experimental medications and augmentation strategies.